Aura Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aura Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 4 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Aura Biosciences: 7 sponsored US clinical trials, 4 recruiting.

Aura Biosciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Choroidal Melanoma, with 2 trials.

Upper-quartile sponsor footprint

Aura Biosciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 2

Suprachoroidal Administration in Subjects With Metastases to the Choroid

NCT06643884
RECRUITING Phase 3

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690
RECRUITING Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868
RECRUITING

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379
TERMINATED

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

NCT05266430
COMPLETED Phase 2

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530
COMPLETED Phase 1

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 1

Therapeutic Areas

Choroidal Melanoma 2
Indeterminate Lesions 1
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG 1
Non-Muscle Invasive Bladder Urothelial Carcinoma 1
Non-Muscle Invasive Bladder Neoplasms 1
NMIBC 1
Indeterminate Lesions of Eye 1
Urothelial Carcinoma Bladder 1
Uveal Melanoma 1
Non-Muscle Invasive Bladder Carcinoma 1

What is open in the Aura Biosciences pipeline

4 recruiting of 7 indexed (57% open); 2 completed (29%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Choroidal Melanoma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aura Biosciences: open-pipeline peers nationwide

Peers matched on 7 registered trials and 57% open enrollment, not the therapeutic-area sidebar.

Aura Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 6.97.07.077.07.07.1 0%20%40%60% Total trials Recruiting share Aura Biosciences3M4Life Research89bioAbbott Diagnostics DivisionAlimentivBicycleTx LimitedBinghamton UniversityColorado Prevention Center
Aura Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aura Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 57% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aura Biosciences page

7 registered trials is a research-attention snapshot, not an endorsement of Aura Biosciences or any single study.

  • 4 of Aura Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Choroidal Melanoma is the condition Aura Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Choroidal Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aura Biosciences pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.